BIOM3: quote, dividends and indicators for Biomm

Biomm S.A. is a Brazilian biotechnology company founded in 2001, following the partial spin-off of Biobrás S.A., a traditional insulin company in the country. In the spin-off, Biomm incorporated the intellectual property related to recombinant DNA production technology, including international patents and operating assets linked to this technology. In 2002, control of Biobrás was sold to the Danish company Novo Nordisk, while Biomm remained under the control of Guilherme Emrich and Marcos Mares Guia, entrepreneurs connected to the development of health biotechnology in Brazil and to the creation of entities such as Fundação Biominas, ABRABI and the local biotechnology production cluster in Belo Horizonte and surrounding areas. Since then, the company has undergone a restructuring and capitalization process that included the entry of new institutional shareholders and the construction of its own production base.

Biomm’s common shares are traded on B3 under the ticker BIOM3, initially listed on the Bovespa Mais segment starting in 2014. The IPO process was preceded by bylaw reforms aimed at adopting corporate governance practices more aligned with the market and at converting preferred shares into common shares. In the same period, the company sought funding from development banks such as BNDES, BDMG, FAPEMIG and FINEP, focusing on the implementation of a biopharmaceutical industrial unit in Nova Lima, in Minas Gerais, and on the installation of storage and distribution centers in Contagem (MG) and Itajaí (SC). This infrastructure began to support the business model based on importing, storing under controlled temperature conditions and marketing biotechnological drugs in the Brazilian market.

Biomm’s operating model combines the internalization of technology inherited from Biobrás with strategic international partnerships. Initially focused on recombinant insulins, the company expanded its scope to a broader portfolio of biotechnological drugs, especially in the areas of diabetes, oncology, rheumatology, thrombosis and immunomodulation. For several years, revenue was generated mainly from importing drugs produced by third parties abroad, followed by storage in cold rooms and distribution in Brazil through a logistics network specialized in thermolabile products. In 2024, Biomm took an important step by putting its Nova Lima biopharmaceutical plant into operation, validated by ANVISA, and began preparing to produce part of its own drugs in the country.

In the diabetes segment, which is the historical core of Biomm’s activities, the portfolio includes different classes of insulins and analogues, as well as drugs for glycemic control in patients with type 2 diabetes mellitus. Among the products marketed or licensed by the company are Afrezza, an inhaled human insulin powder for adults, described as the only non-injectable insulin commercially available worldwide; Wosulin, a widely used human NPH and regular insulin in Brazil and often distributed in public programs; and Glargilin, a biosimilar biopharmaceutical of long-acting insulin glargine. The diabetes portfolio also includes molecules such as semaglutide, degludec, liraglutide, aspart and lispro, all associated with the treatment of diabetes mellitus, featuring different action profiles and possibilities for therapeutic combination. This set of products positions Biomm as a relevant player in providing solutions for treating the disease in the Brazilian health biotechnology market.

In addition to diabetes, Biomm operates in other biopharmaceutical niches, diversifying its portfolio. In oncology, the company works with bevacizumab, a biosimilar monoclonal antibody used in different types of cancer, and pegfilgrastim, intended to reduce the duration and incidence of febrile neutropenia in patients undergoing chemotherapy, pending ANVISA approval. In the thrombosis field, the company markets Ghemaxan, a biosimilar of enoxaparin sodium indicated for the prevention and treatment of deep vein thrombosis and unstable angina, also used in treatment protocols related to Covid-19. There are also pipeline projects in rheumatology, with molecules such as teriparatide and denosumab for the treatment of osteoporosis and bone complications in cancer, and immunomodulators such as ustekinumab, aimed at treating Crohn’s disease, ulcerative colitis and plaque psoriasis. In ophthalmology, the portfolio includes ranibizumab, aimed at treating severe retinal lesions.

From an operational standpoint, Biomm reports its activities in a single operating segment in its consolidated financial statements. Drug distribution is carried out from facilities certified in good storage and distribution practices, with strict temperature control for thermolabile products between 2°C and 8°C or 15°C and 30°C. Transportation is provided by third-party companies specialized in the pharmaceutical market. The sales force is organized into two main fronts: one dedicated to oncology and antithrombotic drugs and the other focused on diabetes. These teams operate in 21 Brazilian states and the Federal District, interacting with physicians, pharmacists, private health insurers, distributors, pharmacies and government agencies. The customer base is described as diversified, although in 2025 Fundação Oswaldo Cruz and the Ministry of Health accounted for a relevant share of net revenue, reflecting the importance of the relationship with the public sector in its sales model.

Biomm’s activities are deeply embedded in a complex regulatory environment, typical of the Brazilian pharmaceutical sector. The company depends on authorizations and registrations issued by the National Health Surveillance Agency (ANVISA) for the manufacturing, registration and marketing of its products, as well as on the Drug Market Regulation Chamber (CMED) for setting maximum consumer prices and factory prices. These parameters guide the pricing practices adopted by the company in the domestic market. In addition, Biomm is subject to regulation by municipal, state and federal bodies, including city governments for obtaining operating permits, environmental agencies such as COPAM in Minas Gerais, the Fire Department for fire safety certification, the Regional Pharmacy Council and, for certain activities, the Brazilian Army and the Federal Police. The Nova Lima plant operates with a valid environmental operating license and up-to-date safety permits and certifications, which are essential for the operation of a biopharmaceutical plant.

In the environmental, social and governance (ESG) field, Biomm does not currently publish a specific report or consolidated performance document in these areas, nor a structured disclosure of indicators or a materiality matrix to the market. Even so, the company states that it adopts internal practices related to environmental management and social responsibility. Among the initiatives reported are environmental education programs for employees and the local community, structured solid waste management focused on preventing soil and water contamination, and noise monitoring in industrial operations. In social terms, the company says it conducts its relations based on the protection of human rights, non-discrimination, the fight against child labor and labor analogous to slavery, and maintains a Code of Ethics and Conduct disclosed to employees and stakeholders. There are occupational health and safety policies, compliance with Regulatory Standards, the presence of a dedicated safety technician and hiring programs for people with disabilities, young apprentices and interns. These practices, although not consolidated in a formal ESG report, make up the context of Biomm’s governance and corporate responsibility, whose BIOM3 shares remain listed and traded on B3.